Discovery of New Quinazoline Derivatives as VEGFR-2 Inhibitors: Design, Synthesis, and Anti-proliferative Studies


Citar

Texto integral

Resumo

Background: In cancer, Receptor tyrosine kinases (RTKs) are powerful oncoproteins that can lead to uncontrolled cell proliferation, angiogenesis, and metastasis when mutated or overexpressed, making them crucial targets for cancer treatment. In endothelial cells, one of them is vascular endothelial growth factor receptor 2 (VEGFR2), a tyrosine kinase receptor that is produced and is the most essential regulator of angiogenic factors involved in tumor angiogenesis. So, a series of new N-(4-(4-amino-6,7-dimethoxyquinazolin-2-yloxy)phenyl)-N-phenyl cyclopropane-1,1- dicarboxamide derivatives as VEGFR-2 inhibitors have been designed and synthesized.

Methods: The designed derivatives were synthesized and evaluated using H-NMR, C13-NMR, and Mass spectroscopy. The cytotoxicity was done with HT-29 and COLO-205 cell lines. The potent compound was further studied for Vegfr- 2 kinase inhibition assay. Furthermore, the highest activity compound was tested for cell cycle arrest and apoptosis. The molecular docking investigation was also done with the help of the Glide-7.6 program interfaced with Maestro- 11.3 of Schrodinger 2017. The molecular dynamics simulation was performed on the Desmond module of Schrodinger.

Results: Compound SQ2 was observed to have promising cytotoxic activity (IC50 = 3.38 and 10.55 µM) in comparison to the reference drug Cabozantinib (IC50 = 9.10 and 10.66 µM) against HT-29 and COLO-205, respectively. The synthesized compound SQ2 showed VEGFR-2 kinase inhibition activity (IC50 = 0.014 µM) compared to the reference drug, Cabozantinib (IC50 = 0.0045 µM). Moreover, compound SQ2 strongly induced apoptosis by arresting the cell cycle in the G1 and G2/M phases. The docking study was performed to understand the binding pattern of the new compounds to the VEGFR-2 active site. Docking results attributed the potent VEGFR-2 inhibitory effect of the new compounds as they bound to the key amino acids in the active site, Asp1044, and Glu883, as well as their hydrophobic interaction with the receptor's hydrophobic pocket. The advanced computational study was also done with the help of molecular dynamics simulation.

Conclusion: The findings show that the developed derivatives SQ2 and SQ4 are equally powerful as cabozantinib at cellular and enzymatic levels. The apoptosis and cell cycle results show that the proposed compounds are potent. This research has provided us with identical or more potent VEGFR-2 inhibitors supported by the results of docking studies, molecular dynamics simulation, cytotoxic actions, in vitro VEGFR-2 inhibition, apoptosis, and cell cycle arrest.

Sobre autores

Sachin Dhawale

Department of Pharmaceutical Chemistry,, Shreeyash Institute of Pharmaceutical Education and Research Aurangabad

Email: info@benthamscience.net

Pratap Dabhade

Department of Pharmaceutical Chemistry, Y.B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus

Email: info@benthamscience.net

Santosh Mokale

Department of Pharmaceutical Chemistry, Y.B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Dokla, E.M.E.; Fang, C.S.; Abouzid, K.A.M.; Chen, C.S. 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC. Eur. J. Med. Chem., 2019, 182, 111607. doi: 10.1016/j.ejmech.2019.111607 PMID: 31446247
  2. Gu, W.; Dai, Y.; Qiang, H.; Shi, W.; Liao, C.; Zhao, F.; Huang, W.; Qian, H. Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors. Bioorg. Chem., 2017, 72, 116-122. doi: 10.1016/j.bioorg.2017.04.001 PMID: 28411406
  3. Bray, F.; Jemal, A.; Grey, N.; Ferlay, J.; Forman, D. Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol., 2012, 13(8), 790-801. doi: 10.1016/S1470-2045(12)70211-5 PMID: 22658655
  4. Li, J.; Gu, W.; Bi, X.; Li, H.; Liao, C.; Liu, C.; Huang, W.; Qian, H. Design, synthesis, and biological evaluation of thieno2,3-dpyrimidine derivatives as novel dual c-Met and VEGFR-2 kinase inhibitors. Bioorg. Med. Chem., 2017, 25(24), 6674-6679. doi: 10.1016/j.bmc.2017.11.010 PMID: 29146452
  5. Marzouk, A.A.; Abdel-Aziz, S.A.; Abdelrahman, K.S.; Wanas, A.S.; Gouda, A.M.; Youssif, B.G.M.; Abdel-Aziz, M. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation. Bioorg. Chem., 2020, 102, 104090. doi: 10.1016/j.bioorg.2020.104090 PMID: 32683176
  6. Zhang, J.; Jiang, X.; Jiang, Y.; Guo, M.; Zhang, S.; Li, J.; He, J.; Liu, J.; Wang, J.; Ouyang, L. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. Eur. J. Med. Chem., 2016, 108, 495-504. doi: 10.1016/j.ejmech.2015.12.016 PMID: 26717201
  7. Saavedra, O.; Claridge, S.; Zhan, L.; Raeppel, F.; Granger, M.C.; Raeppel, S.; Mannion, M.; Gaudette, F.; Zhou, N.; Isakovic, L.; Bernstein, N.; Déziel, R.; Nguyen, H.; Beaulieu, N.; Beaulieu, C.; Dupont, I.; Wang, J.; Macleod, A.R.; Besterman, J.M.; Vaisburg, A. N3-Arylmalonamides: A new series of thieno3,2-bpyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases. Bioorg. Med. Chem. Lett., 2009, 19(24), 6836-6839. doi: 10.1016/j.bmcl.2009.10.095 PMID: 19896842
  8. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1995, 1(1), 27-30. doi: 10.1038/nm0195-27 PMID: 7584949
  9. Kerbel, R.S. Tumor angiogenesis: Past, present and the near future. Carcinogenesis, 2000, 21(3), 505-515. doi: 10.1093/carcin/21.3.505 PMID: 10688871
  10. Yang, Y.; Shi, L.; Zhou, Y.; Li, H.Q.; Zhu, Z.W.; Zhu, H.L. Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(22), 6653-6656. doi: 10.1016/j.bmcl.2010.09.014 PMID: 20943391
  11. Awazu, Y.; Nakamura, K.; Mizutani, A.; Kakoi, Y.; Iwata, H.; Yamasaki, S.; Miyamoto, N.; Imamura, S.; Miki, H.; Hori, A. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities. Mol. Cancer Ther., 2013, 12(6), 913-924. doi: 10.1158/1535-7163.MCT-12-1011 PMID: 23548264
  12. Qiang, H.; Gu, W.; Huang, D.; Shi, W.; Qiu, Q.; Dai, Y.; Huang, W.; Qian, H. Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2. Bioorg. Med. Chem., 2016, 24(16), 3353-3358. doi: 10.1016/j.bmc.2016.03.061 PMID: 27068889
  13. Arora, A.; Scholar, E.M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther., 2005, 315(3), 971-979. doi: 10.1124/jpet.105.084145 PMID: 16002463
  14. Cohen, P. Protein kinases-The major drug targets of the twenty-first century? Nat. Rev. Drug Discov., 2002, 1(4), 309-315. doi: 10.1038/nrd773 PMID: 12120282
  15. Behdani, M.; Zeinali, S.; Khanahmad, H.; Karimipour, M.; Asadzadeh, N.; Azadmanesh, K.; Khabiri, A.; Schoonooghe, S.; Habibi Anbouhi, M.; Hassanzadeh-Ghassabeh, G.; Muyldermans, S. Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol. Immunol., 2012, 50(1-2), 35-41. doi: 10.1016/j.molimm.2011.11.013 PMID: 22208996
  16. Folkman, J. Role of angiogenesis in tumor growth and metastasis; Elsevier, 2002.
  17. Yakes, F.M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B.; Orf, J.; You, A.; Laird, A.D.; Engst, S.; Lee, L.; Lesch, J.; Chou, Y.C.; Joly, A.H. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther., 2011, 10(12), 2298-2308. doi: 10.1158/1535-7163.MCT-11-0264 PMID: 21926191
  18. Abdel-Rahman, O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: Preclinical and clinical aspects. Crit. Rev. Oncol. Hematol., 2015, 93(1), 18-27. doi: 10.1016/j.critrevonc.2014.05.012 PMID: 24970311
  19. Des Guetz, G.; Uzzan, B.; Nicolas, P.; Cucherat, M.; Morere, J-F.; Benamouzig, R.; Breau, J-L.; Perret, G-Y. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br. J. Cancer, 2006, 94(12), 1823-1832. doi: 10.1038/sj.bjc.6603176 PMID: 16773076
  20. Mannion, M.; Raeppel, S.; Claridge, S.; Zhou, N.; Saavedra, O.; Isakovic, L.; Zhan, L.; Gaudette, F.; Raeppel, F.; Déziel, R.; Beaulieu, N.; Nguyen, H.; Chute, I.; Beaulieu, C.; Dupont, I.; Robert, M.F.; Lefebvre, S.; Dubay, M.; Rahil, J.; Wang, J.; Ste-Croix, H.; Robert Macleod, A.; Besterman, J.M.; Vaisburg, A.N. -(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: A novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(23), 6552-6556. doi: 10.1016/j.bmcl.2009.10.040 PMID: 19854051
  21. Claridge, S.; Raeppel, F.; Granger, M.C.; Bernstein, N.; Saavedra, O.; Zhan, L.; Llewellyn, D.; Wahhab, A.; Deziel, R.; Rahil, J.; Beaulieu, N.; Nguyen, H.; Dupont, I.; Barsalou, A.; Beaulieu, C.; Chute, I.; Gravel, S.; Robert, M.F.; Lefebvre, S.; Dubay, M.; Pascal, R.; Gillespie, J.; Jin, Z.; Wang, J.; Besterman, J.M.; MacLeod, A.R.; Vaisburg, A. Discovery of a novel and potent series of thieno3,2-bpyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. Bioorg. Med. Chem. Lett., 2008, 18(9), 2793-2798. doi: 10.1016/j.bmcl.2008.04.009 PMID: 18434145
  22. Claesson-Welsh, L.; Welsh, M. VEGFA and tumour angiogenesis. J. Intern. Med., 2013, 273(2), 114-127. doi: 10.1111/joim.12019 PMID: 23216836
  23. Lintnerová, L.; García-Caballero, M. Gregáň, F.; Melicherčík, M.; Quesada, A.R.; Dobiaš, J.; Lác, J.; Sališová, M.; Boháč, A. A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex – Medicinal chemistry consequences of a TKs analysis. Eur. J. Med. Chem., 2014, 72, 146-159. doi: 10.1016/j.ejmech.2013.11.023 PMID: 24368209
  24. Abbas, S.E.; Barsoum, F.F.; Georgey, H.H.; Mohammed, E.R. Synthesis and antitumor activity of certain 2,3,6-trisubstituted quinazolin-4(3H)-one derivatives. Bull. Fac. Pharm. Cairo Univ., 2013, 51(2), 273-282. doi: 10.1016/j.bfopcu.2013.08.003
  25. Kumar, M.; Narasimhan, B.; Kumar, P.; Ramasamy, K.; Mani, V.; Mishra, R.K.; Majeed, A.B.A. 4-(1-Aryl-5-chloro-2-oxo-1,2-dihydro-indol-3-ylideneamino)-N-substituted benzene sulfonamides: Synthesis, antimicrobial, anticancer evaluation and QSAR studies. Arab. J. Chem., 2014, 7(4), 436-447. doi: 10.1016/j.arabjc.2013.03.002
  26. Garofalo, A.; Farce, A.; Ravez, S.; Lemoine, A.; Six, P.; Chavatte, P.; Goossens, L.; Depreux, P. Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors. J. Med. Chem., 2012, 55(3), 1189-1204. doi: 10.1021/jm2013453 PMID: 22229669
  27. Barbosa, M.L.C.; Lima, L.M.; Tesch, R.; Sant'Anna, C.M.R.; Totzke, F.; Kubbutat, M.H.G.; Schächtele, C.; Laufer, S.A.; Barreiro, E.J. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. Eur. J. Med. Chem., 2014, 71, 1-14. doi: 10.1016/j.ejmech.2013.10.058 PMID: 24269511
  28. Morabito, A.; Piccirillo, M.C.; Costanzo, R.; Sandomenico, C.; Carillio, G.; Daniele, G.; Giordano, P.; Bryce, J.; Carotenuto, P.; La Rocca, A.; Di Maio, M.; Normanno, N.; Rocco, G.; Perrone, F. Vandetanib: An overview of its clinical development in NSCLC and other tumors. Drugs Today (Barc), 2010, 46(9), 683-698. doi: 10.1358/dot.2010.46.9.1516989 PMID: 20967300
  29. Zhan, Z.; Ai, J.; Liu, Q.; Ji, Y.; Chen, T.; Xu, Y.; Geng, M.; Duan, W. Discovery of anilinopyrimidines as dual inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity. ACS Med. Chem. Lett., 2014, 5(6), 673-678. doi: 10.1021/ml500066m PMID: 24944742
  30. Zhengsheng, Z.; Jing, A.; Qiufeng, L.; Yinchun, J.; Tiantian, C.; Yechun, X.; Meiyu, G.; Wenhu, D. Discovery of anilinopyrimidines as dual inhibitors of c-Met and VEGFR-2: synthesis, SAR, and cellular activity. ACS Med. Chem. Lett., 2014, 5, 673-678.
  31. Christensen, J.G.; Burrows, J.; Salgia, R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett., 2005, 225(1), 1-26. doi: 10.1016/j.canlet.2004.09.044 PMID: 15922853
  32. Yakes, F.M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B.; and Orf, J. 2011. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther., 2011, 10(12), 2298-2308.
  33. Mohassab, A.M.; Hassan, H.A.; Abdelhamid, D.; Gouda, A.M.; Youssif, B.G.M.; Tateishi, H.; Fujita, M.; Otsuka, M.; Abdel-Aziz, M. Design and Synthesis of Novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinases. Bioorg. Chem., 2021, 106, 104510. doi: 10.1016/j.bioorg.2020.104510 PMID: 33279248
  34. Abou-Zied, H.A.; Youssif, B.G.M.; Mohamed, M.F.A.; Hayallah, A.M.; Abdel-Aziz, M. EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules. Bioorg. Chem., 2019, 89, 102997. doi: 10.1016/j.bioorg.2019.102997 PMID: 31136902
  35. Wei, D.; Fan, H.; Zheng, K.; Qin, X.; Yang, L.; Yang, Y.; Duan, Y.; Zhang, Q.; Zeng, C.; Hu, L. Synthesis and anti-tumor activity of 1,4 dioxino 2,3-f quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2. Bioorg. Chem., 2019, 88, 102916. doi: 10.1016/j.bioorg.2019.04.010 PMID: 31026719
  36. Alsaif, N.A.; Taghour, M.S.; Alanazi, M.M.; Obaidullah, A.J.; Alanazi, W.A.; Alasmari, A.; Albassam, H.; Dahab, M.A.; Mahdy, H.A. Identification of new 1,2,4triazolo4,3-aquinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Bioorg. Med. Chem., 2021, 46, 116384. doi: 10.1016/j.bmc.2021.116384
  37. Ubale, P.; Mokale, S.; More, S.; Waghamare, S.; More, V.; Munirathinam, N.; Dilipkumar, S.; Das, R.K.; Reja, S.; Helavi, V.B.; Kollur, S.P. Evaluation of in vitro anticancer, antimicrobial and antioxidant activities of new Cu(II) complexes derived from 4(3H)-quinazolinone: Synthesis, crystal structure and molecular docking studies. J. Mol. Struct., 2022, 1251, 131984. doi: 10.1016/j.molstruc.2021.131984
  38. Qian, F.; Engst, S.; Yamaguchi, K.; Yu, P.; Won, K.A.; Mock, L.; Lou, T.; Tan, J.; Li, C.; Tam, D.; Lougheed, J.; Yakes, F.M.; Bentzien, F.; Xu, W.; Zaks, T.; Wooster, R.; Greshock, J.; Joly, A.H. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res., 2009, 69(20), 8009-8016. doi: 10.1158/0008-5472.CAN-08-4889 PMID: 19808973
  39. Norman, M.H.; Liu, L.; Lee, M.; Xi, N.; Fellows, I.; D'Angelo, N.D.; Dominguez, C.; Rex, K.; Bellon, S.F.; Kim, T.S.; and Dussault, I. 2012. Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives. J. Med. Chem., 2012, 55(5), 1858-1867.
  40. Zhou, S.; Liao, H.; Liu, M.; Feng, G.; Fu, B.; Li, R.; Cheng, M.; Zhao, Y.; Gong, P. Discovery andw biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors. Bioorg. Med. Chem., 2014, 22(22), 6438-6452. doi: 10.1016/j.bmc.2014.09.037 PMID: 25438768
  41. Shaw, D.E. Schrödinger: Desmond Molecular Dynamics System; Schrödinger Release: New York, 2021, p. pp. 4.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2023